Editorial overview: The failing heart as a drug target: Are we finally seeing progress?

Current Opinion in Investigational Drugs

Volumn 6, Issue 9, 2005, Pages 870-873

  Mucke, Hermann A M ^a  

^a HM Pharma Consultancy   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ALAGEBRIUM; ATI 22107; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARDIOVASCULAR AGENT; CARNITINE PALMITOYLTRANSFERASE INHIBITOR; CHYMASE INHIBITOR; CONIVAPTAN; ENALAPRIL; ENOXIMONE; FIBRIC ACID DERIVATIVE; HYDRALAZINE PLUS ISOSORBIDE DINITRATE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MATRIX METALLOPROTEINASE INHIBITOR; METOPROLOL; NESIRITIDE; OMAPATRILAT; OXFENICINE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PHOSPHODIESTERASE III INHIBITOR; SUN C 8257; TEI E 548; TOLVAPTAN; TY 51076; UNCLASSIFIED DRUG; VASOPEPTIDASE INHIBITOR; VASOPRESSIN RECEPTOR ANTAGONIST; 3',5' CYCLIC NUCLEOTIDE PHOSPHODIESTERASE; CHYMASE; PHOSPHODIESTERASE III; PROTEINASE INHIBITOR; SERINE PROTEINASE;

ANGIONEUROTIC EDEMA; CLINICAL TRIAL; DRUG APPROVAL; DRUG EFFICACY; DRUG INDUSTRY; DRUG MECHANISM; DRUG SAFETY; DRUG STRUCTURE; DRUG TARGETING; EDITORIAL; ENZYME INHIBITION; HEART ARRHYTHMIA; HEART FAILURE; HEART VENTRICLE REMODELING; HUMAN; HYPERTENSION; NONHUMAN; ANIMAL; CONGESTIVE HEART FAILURE; DRUG ANTAGONISM; DRUG DESIGN; HEART MUSCLE; PATHOLOGY; PHYSIOLOGY;

3',5'-CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; ANIMALS; CHYMASES; DRUG DESIGN; HEART FAILURE, CONGESTIVE; HUMANS; MYOCARDIUM; PROTEASE INHIBITORS; SERINE ENDOPEPTIDASES;

EID: 24644445980     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (14)

1. Jessup M, Brozena S: Heart Failure. N Engl J Med (2003) 348(20):2007-2018.
2. Hedrich O, Patten RD, Denofrio D: Current treatment options for CHF management: Focus on the renin-angiotensin-aldosterone system. Curr Treat Options Cardiovasc Med (2005) 7(1):3-13.
3. Port JD, Bristow MR: Altered β-adrenergic receptor gene regulation and signaling in chronic head failure. J Mol Cell Cardiol (2001) 33(5):887-905.
4. Yancy CW, Saltzberg MT, Berkowitz RL, Bertolet B, Vijayaraghavan K, Burnham K, Oren RM, Walker K, Horton DP, Silver MA: Safety and feasibility of using serial infusions of nesiritide for heart failure in an outpatient setting (from the FUSION I trial). Am J Cardiol (2004) 94(5):595-601.
5. Packer M, Califf RM, Konstam MA, Krum H, McMurray JJ, Rouleau JL, Swedberg K: Comparison of omapatrilat and enalapril in patients with chronic heart failure: The Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE). Circulation (2002) 106(8):920-926.
6. Gheorghiade M, Orlandi C, Burnett JC, Demets D, Grinfeld L, Maggioni A, Swedberg K, Udelson JE, Zannad F, Zimmer C, Konstam MA: Rationale and design of the multicenter, randomized, double-blind, placebo-controlled study to evaluate the Efficacy of Vasopressin antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST). J Card Fail (2005) 11(4):260-269.
7. Hara M, Ono K, Hwang MW, Iwasaki A, Okada M, Nakatani K, Sasayarna S, Matsumori A: Evidence for a role of mast cells in the evolution to congestive heart failure. J Exp Med (2002) 195(3):375-381.
8. Jung AS, Quaile MP, Mills GD, Bednarik DP, Houser SR, Margulies KB: Pharmacological effects of ATI22-107 [2-(2-{2-[2-chloro-4-(6-oxo-1,4,5,6-tetrahydro-pyridazin-3-yl)-phenoxy]- acetylamino}-ethoxy-methyl)-4-(2-chloro-phenyl)-6-methyl-1, 4-dihydro-pyridine-3,5-dicarboxylic acid dimethyl ester], a novel dual pharmacophore, on myocyte calcium cycling and contractility. J Pharmacol Exp Ther (2005) 312(2):517-524.
9. Stanley WC, Recchia FA, Lopaschuk GD: Myocardial substrate metabolism in the normal and failing heart. Physiol Rev (2005) 85(3):1093-1129.
10. Lionetti V, Linke A, Chandler MP, Young ME, Penn MS, Gupte S, d'Agostino C, Hintze TH, Stanley WC, Recchia FA: Carnitine palmitoyl transferase-I inhibition prevents ventricular remodeling and delays decompensation in pacing-induced heart failure. Cardiovasc Res (2005) 66(3):454-461.
11. Goikoetxea MJ, Beaumont J, Diez J: Peroxisome proliferator-activated receptor α and hypertensive heart disease. Drugs (2004) 64(Suppl 2):9-18.
12. Little WC, Zile MR, Kitzman DW, Hundley WG, O'Brien TX, Degroof RC: The effect of alagebrium chloride (ALT-711), a novel glucose cross-link breaker, in the treatment of elderly patients with diastolic heart failure. J Card Fail (2005) 11(3):191-195.
13. Peterson JT, Li H, Dillon L, Bryant JW: Evolution of matrix metalloprotease and tissue inhibitor expression during heart failure progression in the infarcted rat. Cardiovasc Res (2000) 46(2):307-315.
14. Brown RD, Ambler SK, Mitchell MD, Long CS: The cardiac fibroblast: Therapeutic target in myocardial remodeling and failure. Annu Rev Pharmacol Toxicol (2005) 45:657-687.